Medical Condition News

RSS

Markers that cause primary liver cancer identified

Hepatocellular carcinoma (HCC) or primary liver cancer forms in the epithelial tissue of the liver and is most commonly caused by the hepatitis B virus (HBV) or hepatitis C virus (HCV). In the U.S., the National Cancer Institute (NCI) estimates that 15,000 men and 6,000 women are diagnosed with HCC each year.

21 Oct 2009

Celsion completes patient enrollment in its global Phase III ThermoDox trial

Celsion Corporation announced today that it has completed a critical regulatory step in the countries of China and Japan to rapidly enroll patients in its global Phase III ThermoDox trial for the treatment of Hepatocellular Carcinoma (HCC), also known as primary liver cancer.

21 Oct 2009

Shire to file a Biologics License Application for REPLAGAL with the FDA

Shire plc, the global specialty biopharmaceutical company, announces plans to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease, by the end of the year.

21 Oct 2009

King Pharmaceuticals receives FDA complete response letter for CorVue NDA

King Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for CorVue™ (binodenoson) for injection.

21 Oct 2009

Professor secures grant for further research on immunotherapy strategies

Venuprasad K. Poojary, Ph.D., assistant professor at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, has secured a two-year federal grant for almost $1 million to further his research into creating more effective immunotherapy strategies for cancer treatment.

21 Oct 2009

New results from ADVANCE provide important insights to reduce diabetes complications

New results from ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation), the largest clinical trial ever performed in patients with type 2 diabetes worldwide, provide important insights into the therapeutic strategy to adopt for efficient and safe blood glucose control aimed at the reduction of severe diabetes complications.

21 Oct 2009

Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis

Bristol-Myers Squibb Company announced today that new clinical data support continued development of a subcutaneous administration of ORENCIA® (abatacept) for patients with moderate to severe rheumatoid arthritis.

21 Oct 2009

NIH awards $2.1 million to a team of scientists for schizophrenia research

The US National Institutes of Health (NIH) has awarded a $2.1 million "Grand Opportunity" (GO) grant to a team of researchers - led by Prof. Todd Lencz at the Feinstein Institute for Medical Research, New York, and Prof.Ariel Darvasi of the Silberman Institute of Life Sciences at the Hebrew University of Jerusalem - to conduct a study on the genetic basis of schizophrenia..

21 Oct 2009

Carcinoembryonic antigen co-discoverer Dr. Phil Gold to be inducted into The Canadian Medical Hall of Fame

Prof. Heather Munroe-Blum, Principal and Vice-Chancellor of McGill University, and the Hon. Arthur T. Porter, Director General and CEO of the McGill University Health Centre (MUHC), welcome the news that Dr. Phil Gold is to be inducted into The Canadian Medical Hall of Fame. In 1965, Dr. Gold co-discovered the carcinoembryonic antigen (CEA), the first clinically useful human tumour marker that revolutionized the diagnosis and management of cancer.

21 Oct 2009

MIRP surgery carries higher risk of impotence and incontinence than traditional surgery

A new study debating the effectiveness of minimally invasive prostate surgery is not telling the whole story, warns Dr. David B. Samadi, Chief of the Division of Robotics and Minimally Invasive Surgery in the Department of Urology at The Mount Sinai Medical Center in New York.

21 Oct 2009

Study of aldosterone antagonist usage among patients hospitalised with heart failure published

A study published today in JAMA (October 21) by Nancy M. Albert and colleagues, exploring aldosterone antagonist usage among US patients hospitalised with heart failure, found that only one-third of patients meeting current US Clinical Practice Guidelines criteria were actually being treated.

21 Oct 2009

Herrick Foundation's $3M grant for cancer research

The Barbara Ann Karmanos Cancer Institute announced today it received a $3 million grant from the Herrick Foundation. The initial gift of $1 million launches The Herrick Foundation Cancer Research Challenge, a special initiative to increase research funding at the Karmanos Cancer Institute over the next four years. The additional commitment of $2 million will be given in match funding.

21 Oct 2009

Cheering for your favorite baseball team: Is it hazardous to your health?

A study, led by cardiologist, Dr. Franklin Zimmerman of Columbia University, will use an ambulatory blood pressure monitor (ABPM) to determine whether cheering for your favorite baseball team is hazardous to your health.

21 Oct 2009

Genzyme commences patient enrollment in Genz-112638 phase 3 trials

Genzyme Corporation today announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule.

21 Oct 2009

New tools needed to identify men and women at risk for the most aggressive cancers

Twenty years of screening for breast and prostate cancer - the most diagnosed cancer for women and men - have not brought the anticipated decline in deaths from these diseases, argue experts from the University of California, San Francisco and the University of Texas Health Science Center at San Antonio in an opinion piece published in the "Journal of the American Medical Association."

21 Oct 2009

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

A group led by Dr. Dieter Br-mme at the University of British Columbia has demonstrated that glycosaminoglycans (GAGs) contribute to skeletal abnormalities in patients with lysosomal storage diseases. Their report can be found in the November 2009 issue of The American Journal of Pathology.

21 Oct 2009

Researchers study reading and written comprehension skills of deaf youngsters

A group of researchers at Seville University, headed by Isabel de los Reyes Rodríguez Ortiz, is analysing the reading comprehension processes of deaf youngsters, a factor closely linked to their level of expression, both verbal and using sign language.

21 Oct 2009

Statewide Initiative to increase sudden cardiac arrest survival rates launched in Minnesota

Medtronic Foundation and Take Heart Minnesota™ today announced a comprehensive statewide initiative, the first in the nation, designed to increase sudden cardiac arrest (SCA) survival rates. SCA is a condition in which the heart abruptly stops without warning. More than 4,500 cases of SCA were reported in Minnesota in 2008, an average of 12.5 incidences per day.

21 Oct 2009

Palmerolide A: Real hope for cancer treatment

A targeted chemotherapy for the treatment of skin cancer is one step closer, after a team of University of Alberta researchers successfully synthesized a natural substance that shows exceptional potential to specifically treat this often fatal disease.

21 Oct 2009

V8 100% vegetable juice aids in weight loss and lowers blood pressure

Decades of studies have documented the link between eating a diet rich in vegetables and multiple health benefits, yet nearly eight out of 10 people worldwide fall short of the daily recommendation.

21 Oct 2009

Medical Condition News

Markers that cause primary liver cancer identified

Celsion completes patient enrollment in its global Phase III ThermoDox trial

Shire to file a Biologics License Application for REPLAGAL with the FDA

King Pharmaceuticals receives FDA complete response letter for CorVue NDA

Professor secures grant for further research on immunotherapy strategies

New results from ADVANCE provide important insights to reduce diabetes complications

Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis

NIH awards $2.1 million to a team of scientists for schizophrenia research

Carcinoembryonic antigen co-discoverer Dr. Phil Gold to be inducted into The Canadian Medical Hall of Fame

MIRP surgery carries higher risk of impotence and incontinence than traditional surgery

Study of aldosterone antagonist usage among patients hospitalised with heart failure published

Herrick Foundation's $3M grant for cancer research

Cheering for your favorite baseball team: Is it hazardous to your health?

Genzyme commences patient enrollment in Genz-112638 phase 3 trials

New tools needed to identify men and women at risk for the most aggressive cancers

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

Researchers study reading and written comprehension skills of deaf youngsters

Statewide Initiative to increase sudden cardiac arrest survival rates launched in Minnesota

Palmerolide A: Real hope for cancer treatment

V8 100% vegetable juice aids in weight loss and lowers blood pressure

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News